Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has signed a pharmaceutical contract manufacturing agreement worth approximately KRW 92.8B (USD 70.6M) with Merck Sharp & Dohme (Switzerland) GmbH.
📊 [Key Disclosure Details & Financial Figures]
- Contract Title: Contract Manufacturing Agreement for Pharmaceutical Products
- Contract Classification: Other Sales and Supply Contract
- Counterparty: Merck Sharp & Dohme (Switzerland) GmbH
- Contract Amount: KRW 92,769,116,464 (USD 70,579,060 / Applied Exchange Rate: USD/KRW 1,314.40)
- Recent Annual Revenue: KRW 3,001,295,197,683 (Based on 2022 consolidated financial statements)
- Ratio to Recent Annual Revenue: 3.09%
- Contract Execution Date: March 12, 2024
- Contract Period: March 1, 2024 ~ December 31, 2032
- Other Remarks: Contract end date is subject to change based on mutual agreement
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Revenue Recognition and Contract Condition Adjustments over the Term
This disclosure reports a newly executed contract manufacturing agreement worth approximately KRW 92.8B with Merck Sharp & Dohme (Switzerland) GmbH. Because sales and supply contracts remain subject to potential amendments in value or duration depending on mutual agreement, tracking whether the contract value is recognized as actual revenue as scheduled is essential. Verifying this progression helps investors evaluate the concrete financial impact of the deal on long-term earnings, which can be monitored through subsequent Quarterly, Half-Yearly, and Annual Reports, as well as notes to financial statements.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
